OverviewSuggest Edit
Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Its commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration and retinal vein occlusion.
| Type | Public | |
| Founded | 2003 | |
| HQ | Alpharetta, US | Map |
| Website | alimerasciences.com | |
| Employee Ratings | More |
Recent NewsAll News
- Retinal Drugs And Biologics Market 2019: Booming Worldwide by Key Players like Alimera Sciences, Janssen Biotech, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, Ocular Therapeutix, Inc.
- Retinal Drugs and Biologics Global Market 2019 Top Key Players – ALLERGAN, AbbVie , Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum and Forecast to 2023
- Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress
- Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting
Key People/Management at Alimera Sciences
Ken Greene
CSO
Susan Caballa
Sr. Vice President, Regulatory & Medical Affairs
Philip Ashman
SVP & European Managing Director
Rick Eiswirth
President & CFO
Dave Holland
SVP of Sales & Marketing
Report incorrect company information
Alimera Sciences Office Locations
Alimera Sciences has offices in Alpharetta, Berlin, Hampshire and Lisbon
Alpharetta, US (HQ)
6120 Windward Pkwy #290
Berlin, DE
21 Cicerostraße
Hampshire, GB
Wellesley Rd
Report incorrect company information
Alimera Sciences Financials and Metrics
Alimera Sciences Revenue
Alimera Sciences's revenue was reported to be $46.97 m in FY, 2018
| USD | |
|---|---|
Revenue (FY, 2018) | 47.0m |
Net income (FY, 2018) | (16.4m) |
EBIT (FY, 2018) | (9.7m) |
Market capitalization (18-Mar-2019) | 82.3m |
Closing stock price (18-Mar-2019) | 1.2 |
Cash (31-Dec-2018) | 13.0m |
EV | 107.2m |
Alimera Sciences's current market capitalization is $82.3 m.
Annual
Quarterly
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 23.1m | 41.3m | 42.0m | 61.4m | 61.3m | 48.1m | 39.3m | 23.9m | 16.6m | 33.9m | 26.7m | 26.9m | 25.6m |
Accounts Receivable | 464.0k | 1.3m | 1.0m | 1.1m | 3.4m | 7.7m | 9.4m | 9.1m | 13.3m | 13.4m | 10.8m | 13.6m | 13.5m |
Inventories | 3.0m | 1.2m | 1.4m | 1.7m | 2.1m | 1.6m | 1.7m | 1.4m | 1.2m | 913.0k | 802.0k | 1.1m | 1.7m |
Current Assets | 30.1m | 46.5m | 47.5m | 67.3m | 70.3m | 61.1m | 53.4m | 37.2m | 34.7m | 51.6m | 40.5m | 44.3m | 43.6m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (31.5m) | (20.8m) | (19.6m) | (26.7m) | (9.8m) | (18.4m) | (19.9m) | (11.1m) | (18.0m) | (27.2m) | (6.7m) | (9.5m) | (14.8m) | (7.7m) | (11.7m) | (15.1m) |
Depreciation and Amortization | 101.0k | 36.0k | 69.0k | 151.0k | 558.0k | 1.2m | 1.9m | 689.0k | 1.4m | 2.1m | 666.0k | 1.3m | 2.0m | 649.0k | 1.3m | 1.9m |
Inventories | (2.2m) | 548.0k | 400.0k | (9.0k) | (455.0k) | (16.0k) | (88.0k) | 164.0k | 301.0k | 612.0k | (361.0k) | (719.0k) | (1.3m) | 299.0k | (651.0k) | (250.0k) |
Accounts Payable | 717.0k | 111.0k | 122.0k | 1.3m | 272.0k | (1.2m) | (1.4m) | (1.5m) | 264.0k | (2.1m) | (1.1m) | 572.0k | 98.0k | (992.0k) | 167.0k | (779.0k) |
| USD | Y, 2018 |
|---|---|
EV/EBIT | -11.1 x |
EV/CFO | -9.3 x |
Financial Leverage | 19.9 x |
Report incorrect company information
Alimera Sciences Online and Social Media Presence
2.07k Twitter followers
Alimera Sciences has 2.07k Twitter Followers. The number of followers has increased 1.5% month over month and increased 4.2% quarter over quarter
Report incorrect company information
Twitter Engagement Stats for @AlimeraSciences
1.4k
Tweets
745
Following
2.1k
Followers
5
Tweets last 30 days
2.2
Avg. likes per Tweet
100%
Tweets with engagement
Alimera Sciences News and Updates
February 12, 2019
Retinal Drugs And Biologics Market 2019: Booming Worldwide by Key Players like Alimera Sciences, Janssen Biotech, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, Ocular Therapeutix, Inc.
The retina is a delicate and sensitive part of the human eye. It is helpful in processing and receiving the light and converts them into neural signals and passes them to the brain for the activities that are done visually. The retinal health disorders include age-related macular degeneration, infec…
January 17, 2019
Retinal Drugs and Biologics Global Market 2019 Top Key Players – ALLERGAN, AbbVie , Alimera Sciences, Janssen Biotech, Swedish Orphan Biovitrum and Forecast to 2023
Wiseguyreports.Com Added New Market Research Report On -“Retinal Drugs and Biologics Market 2019 Key Players, Applications and Future Demand Forecast to 2023 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday
September 17, 2018
Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress
ATLANTA, Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that nine clinical presentations from real world ILUVIEN® usage in Europe and the U.S. will be ...
September 13, 2018
Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting
ATLANTA, Sept. 13, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN® during the ...
September 11, 2018
Global Diabetic Macular Edema Treatment Market 2018-2022 - Key Vendors are Allergan Alimera Sciences, Bausch Health, F. Hoffmann-La Roche & Regeneron Pharmaceuticals
DUBLIN, Sept 11, 2018 /PRNewswire/ -- The "Global Diabetic Macular Edema Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Diabetic Macular Edema Treatment Market to grow at a CAGR of 1.45% during the period 2018-2022. Global Diabetic...
September 04, 2018
Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock
ATLANTA, Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates...
Report incorrect company information
Alimera Sciences Blogs
February 18, 2019
Alimera Sciences Reports Record Fourth Quarter and 2018 Results
Fourth Quarter 2018 Highlights Fourth quarter 2018 consolidated net revenue up 66% International segment revenue increased 138% over the prior year period Net Loss of $1.2 million vs. Net Loss of $7.2 million during 4Q17 Positive Adjusted EBITDA of $2.4 million vs.
February 05, 2019
Alimera Sciences Announces Approval For ILUVIEN® in Lebanon
Lebanon will be the second Middle Eastern country to approve ILUVIEN ATLANTA, February 5, 2018 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that product registration has been
February 04, 2019
Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019
ATLANTA, February 4th, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the three and twelve month periods ended December 31, 2018
January 07, 2019
Alimera Sciences Affirms Record 2018 Revenues
Anticipates 2018 GAAP Net Revenue in Excess of $45 Million ATLANTA, January 7, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today affirmed that it expects record annual 2018 and fourth quarter
December 17, 2018
Alimera Sciences Announces Pricing Approval For ILUVIEN® in the U.A.E.
Alimera Sciences Announces Pricing Approval For ILUVIEN® in the U.A.E.
Jonathan.Lorin…
Sun, 12/16/2018 - 22:08
Alimera Sciences Announces Pricing Approval For ILUVIEN® in the U.A.E.
Dec 17, 2018
This release is a backfill from a News Wire
…
November 29, 2018
Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
Neil.Lawrence@…
Thu, 11/29/2018 - 07:37
Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
Nov 29, 2018
This release is a backfill from a News Wire
General…
Alimera Sciences Frequently Asked Questions
When was Alimera Sciences founded?
Alimera Sciences was founded in 2003.
Who are Alimera Sciences key executives?
Alimera Sciences's key executives are Ken Greene, Susan Caballa and Philip Ashman.
How many employees does Alimera Sciences have?
Alimera Sciences has 118 employees.
What is Alimera Sciences revenue?
Latest Alimera Sciences annual revenue is $47 m.
What is Alimera Sciences revenue per employee?
Latest Alimera Sciences revenue per employee is $398.1 k.
Who are Alimera Sciences competitors?
Competitors of Alimera Sciences include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.
Where is Alimera Sciences headquarters?
Alimera Sciences headquarters is located at 6120 Windward Pkwy #290, Alpharetta.
Where are Alimera Sciences offices?
Alimera Sciences has offices in Alpharetta, Berlin, Hampshire and Lisbon.
How many offices does Alimera Sciences have?
Alimera Sciences has 4 offices.